Tirzepatide vs Semaglutide: What a 2026 Comparison Found

A new indirect comparison suggests that tirzepatide was associated with greater weight reduction than semaglutide in adults with obesity or overweight without type 2 diabetes, while the reported safety profiles were generally similar. The analysis did not compare the two medicines in the same randomised trial, so its findings should be read as a cross-trial comparison rather than proof of a direct head-to-head difference.

What did the tirzepatide and semaglutide comparison examine?

The study, published in International Journal of Obesity on 28 September 2026, assessed an indirect treatment comparison using placebo as the common reference. The authors compared results from the SURMOUNT-1 trial of tirzepatide with results from STEP 1 of semaglutide. Both trial programmes evaluated adults with obesity, or adults with overweight and at least one obesity-related complication, who did not have type 2 diabetes.

The comparison used the primary trial endpoints, at week 72 for SURMOUNT-1 and week 68 for STEP 1. The analysis considered weight, body mass index, waist circumference, glycated haemoglobin, fasting plasma glucose, diastolic blood pressure, HDL, and selected body-composition measures. The authors reported both unadjusted comparisons and comparisons adjusted for sex, and for sex and ethnicity.

This design matters. An indirect treatment comparison can align results from separate studies, but differences in recruitment, background care, trial conduct, measurement and participant characteristics can affect the estimate. It is not the same as assigning participants to tirzepatide or semaglutide within one controlled trial.

What differences did the authors report?

For the efficacy estimand, the unadjusted comparison associated the higher tirzepatide regimens with greater weight reduction than semaglutide. The estimated differences were 5.10 kg for one comparison and 6.50 kg for the other, with 95% confidence intervals of 3.57 to 6.63 kg and 4.97 to 8.03 kg respectively. The analysis also reported statistically significant differences for the proportions of participants reaching at least 10%, 15% and 20% weight reduction.

The same comparisons were associated with lower body mass index and waist circumference. The estimated body-mass-index differences were 1.87 kg/m2 and 2.37 kg/m2, while the waist-circumference differences were 5.25 cm and 5.75 cm. These are estimates from the indirect model, not measurements from a trial in which participants were randomised between the two medicines.

The authors also reported smaller differences in glycated haemoglobin and fasting plasma glucose. The estimated differences in glycated haemoglobin were 0.08 and 0.10 percentage points, and the fasting-plasma-glucose differences were 1.69 and 2.52 mg/dL. The direction of these findings was broadly consistent in the adjusted and unadjusted analyses.

What did the analysis say about body composition?

Body composition was available for a subset of participants. In that subset, the comparison involving the higher tirzepatide regimen was associated with a 3.50 percentage-point lower body-fat percentage and a 3.40 percentage-point higher lean-mass percentage than the semaglutide comparison. The confidence intervals were wide enough to show that these estimates should be interpreted with care.

Body weight is not the same measurement as fat mass or lean mass. A study can report a difference in total weight without establishing how every component changed. The body-composition findings therefore add context, but they do not remove the limitations of the indirect design or establish that the same change would occur in every population.

The study evaluated medicines used in their clinical trial programmes. Tirzepatide and semaglutide are pharmaceutical products with their own regulatory status. A research-use-only reagent is not the same thing as an authorised pharmaceutical product and must not be treated as a substitute for it.

How similar were the reported safety profiles?

The authors described the safety profiles of tirzepatide and semaglutide as generally similar in the indirect comparison. This summary does not mean that every adverse event, discontinuation pattern or risk estimate was identical. It means that the overall comparison did not identify a broad safety separation under the methods used.

Safety interpretation is particularly sensitive to how trials define, collect and report adverse events. The analysis was designed to estimate relative efficacy and safety through a common placebo reference. It was not designed to replace the full safety reports of the individual trials, product information or regulatory assessments.

What are the main limitations?

The most important limitation is the absence of a direct randomised comparison. The source article used data from separate studies with different protocols and trial populations. Adjusting for selected participant characteristics can reduce some imbalance, but it cannot guarantee that all relevant differences have been accounted for.

The comparison also used different endpoint timings, with week 68 for one programme and week 72 for the other. The authors performed adjusted and unadjusted analyses, and the broad direction of the findings was consistent, but consistency across models does not turn an indirect estimate into a head-to-head result.

Finally, the analysis focused on adults without type 2 diabetes who met the trial eligibility criteria. Its estimates should not be extended automatically to people with different conditions, different background treatments or different clinical characteristics. The paper is useful for understanding the available cross-trial evidence, not for making an individual treatment decision.

For research communication, the practical lesson is to keep the comparison attached to its design. A headline can describe the direction of the estimate, but the article should retain the words “indirect comparison” and identify the two underlying trial programmes. That distinction helps readers separate a useful evidence synthesis from a claim of direct superiority.

Related on Peptra Labs

For laboratory readers, the tirzepatide research guide summarises the compound’s research context. The broader comparison of retatrutide, tirzepatide and semaglutide explains how receptor activity differs across these compounds. For general research documentation, see the Research Use Only boundaries. Peptra Labs materials are intended for laboratory research and are not instructions for human use.

References

1. Indirect comparative efficacy and safety of tirzepatide vs semaglutide for the treatment of obesity or overweight in patients without type 2 diabetes. International Journal of Obesity. 2026. PMID 42806056.
2. DOI: 10.1038/s41366-026-02229-6.

The products referenced on this site are supplied for laboratory research use only. They are not medicines and are not intended for human or veterinary use. This article summarises published research for informational purposes and is not medical advice. Statements about third-party studies belong to their authors.